TVAX-008

DRUG3 trials

Sponsors

Grand Theravac Life Sciences (Nanjing) Co., Ltd.

Conditions

Chronic Hepatitis BChronic Hepatitis B VirusHBV Infection

Early Phase 1

Study to Evaluate Immunogenicity and Safety of TVAX-008 Injection in Non/Treated Chronic Hepatitis B Patients With HBsAg≤20IU/ml or HBsAg Negative Without Serological Conversion

Active, not recruitingNCT07204236

Grand Theravac Life Sciences (Nanjing) Co., Ltd.Chronic Hepatitis B

Start: 2024-01-18End: 2026-03-01Updated: 2025-10-02

Phase 2

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B Patients

Active, not recruitingNCT07179653

Grand Theravac Life Sciences (Nanjing) Co., Ltd.HBV Infection

Start: 2025-01-22End: 2026-12-31Target: 48Updated: 2025-09-18

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Treated Patients With Chronic Hepatitis B

Active, not recruitingNCT07190742

Grand Theravac Life Sciences (Nanjing) Co., Ltd.Chronic Hepatitis B Virus

Start: 2023-06-01End: 2026-05-01Target: 80Updated: 2025-09-24